ROS-Responsive Biomimetic Nanocomplexes of Liposomes and Macrophage-Derived Exosomes for Combination Breast Cancer...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Breast cancer is a leading global cancer in women, with chemotherapy facing challenges like multidrug resistance and toxicity.
• Nanotechnology offers solutions for chemotherapy limitations, but nanoparticles often face rapid clearance by the mononuclear phagocyte system (MPS).

Purpose of the Study:

• To develop a ROS-responsive biomimetic nanocomplex for co-delivering docetaxel (DTX) and Bcl-2 siRNA to mitigate chemotherapy toxicity and enhance drug delivery efficiency.
• To overcome the MPS barrier and improve the circulation time of externally introduced nanoparticles.

Main Methods:

• Biomimetic nanocomplexes (E-cLip-DTX/si) were created by combining ROS-responsive cationic liposomes with macrophage-derived exosomes.
• Docetaxel (DTX) and Bcl-2 siRNA were encapsulated as model drugs within the nanocomplexes.
• Antitumor efficacy was validated through in vitro and in vivo studies.

Main Results:

• The E-cLip-DTX/si nanocomplex demonstrated ROS-responsiveness, effectively promoting tumor cell apoptosis.
• In vivo studies in a breast cancer mouse model showed enhanced tumor accumulation, significant antitumor effects, and a favorable safety profile.
• The nanocomplex successfully prolonged circulation time, overcoming MPS clearance.

Conclusions:

• The developed ROS-responsive biomimetic nanocomplex is a promising drug delivery platform for breast cancer treatment.
• This platform offers controlled drug release, enhanced biocompatibility, and overcomes key challenges in chemotherapy delivery.
• The study highlights the potential of exosome-liposome hybrid nanostructures for effective cancer therapy.